Panacea Biotec subsidiary receives GST show cause notice over Rs 4.06 crore input tax credit claim

What Happened

A subsidiary of Panacea Biotec Limited has been served a show cause notice by GST authorities challenging an input tax credit (ITC) claim amounting to Rs 4.06 crore. The notice, issued under the provisions of the Goods and Services Tax Act, requires the company to provide detailed justification and supporting documentation for the disputed credit within a stipulated timeframe.

While the exact date of issuance has not been disclosed in public reports, this enforcement action appears to centre on the authenticity and eligibility of invoices on which the ITC was claimed. GST authorities have indicated preliminary findings that suggest the credit claimed may not meet the statutory conditions laid out under GST law, namely that supplies must be genuine, invoices must be validly issued, and goods or services must have been actually received and used for business purposes.

Panacea Biotec, a pharmaceutical and vaccine manufacturer with operations across India, is subject to the standard GST compliance framework applicable to the pharmaceutical sector. The group company in question would have filed returns reflecting these ITC amounts, triggering the present audit scrutiny.

Why It Matters

This action reflects the GST administration's intensified focus on controlling ITC fraud and misuse—one of the most significant revenue leakages under the GST regime. Input tax credit represents a credit of tax paid at earlier stages and is fundamental to the GST's design as a destination-based tax. However, fraudulent or inflated ITC claims undermine revenue collection and create unequal competitive advantage for compliant businesses.

The Rs 4.06 crore quantum indicates a material discrepancy that has warranted formal notice rather than routine correspondence. For a pharmaceutical company of Panacea Biotec's scale, such a notice signals that the authorities have identified patterns suggestive of either invoicing irregularities, supply chain documentation gaps, or eligibility threshold violations.

This development is particularly significant because it highlights the GST administration's data analytics capabilities and cross-matching protocols. Tax authorities now routinely use GSTR-2B (auto-populated ITC eligibility statements) and supplier-level reporting to identify anomalies. A show cause notice at this stage suggests the discrepancies did not emerge from simple computational errors but from substantive questions about the claim's validity.

For the broader pharmaceutical sector—often subject to heightened GST scrutiny due to supply chain complexities and inter-state transactions—this notice serves as a reminder that claimed ITC must be supported by immaculate documentation and genuine business transactions.

Practical Impact

For Panacea Biotec's finance and compliance teams, the immediate priority is to collate all invoices, delivery challan copies, payment records, and consumption/usage certificates relevant to the disputed Rs 4.06 crore claim. The show cause notice will specify a response deadline (typically 15–30 days from issuance), during which the company must demonstrate either that the credit was legitimate or that corrections should be made.

Failure to provide satisfactory explanation may result in: (a) demand for reversal of the ITC with interest at 18% per annum from the date of original claim, and (b) penalties of up to 10% of the tax amount in question (approximately Rs 40 lakh plus interest). In egregious cases, authorities may proceed to adjudication and potentially impose higher penalties under Section 122 of the CGST Act.

CFOs and tax managers at comparable pharmaceutical and biotech companies should treat this as a governance signal to conduct preventive audits of their own ITC positions, particularly examining: - Invoices from new or infrequently used suppliers - Claims under reverse charge mechanism (Form GST TRAN-1) - Credit notes issued by suppliers - Any supplies where physical receipt cannot be corroborated

From a compliance process perspective, firms should strengthen invoice verification protocols, implement three-way matching (invoice–receipt–payment), and maintain contemporaneous evidence of actual use of inputs in manufacturing or service delivery. The GST administration's message is unambiguous: claimed ITC must be defensible within 90 seconds of an audit query.

Key Takeaways

• →Panacea Biotec subsidiary faces Rs 4.06 crore ITC demand; show cause notice requires detailed justification within stipulated deadline, with potential reversal plus 18% interest and penalties if claim cannot be substantiated
• →GST authorities are deploying data analytics and GSTR cross-matching to identify ITC anomalies; pharmaceutical companies face heightened scrutiny due to supply chain complexity and inter-state transaction patterns
• →Finance teams must immediately audit ITC documentation—invoices, delivery proof, payment records, and usage evidence; failure to respond adequately may trigger demand proceedings and penalties up to 10% of the tax amount
• →Broader message for biotech and pharma sector: preventive compliance audits are essential; companies should strengthen three-way matching protocols and maintain contemporaneous evidence of actual receipt and use of inputs
• →Interest accrual begins from the date of original ITC claim; even if demand is eventually reversed on appeal, interest cost to taxpayer is substantial, making proactive documentation discipline essential

Disclaimer: This update is for general information only and does not constitute legal, tax or professional advice. Regulatory positions may change. Please consult APRA & Associates LLP for advice specific to your business. Contact us.